Phase I Trial of Intratumoral Administration of HF10, A Replication Competent Herpes Simplex Virus Type 1, in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Trial Profile

Phase I Trial of Intratumoral Administration of HF10, A Replication Competent Herpes Simplex Virus Type 1, in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2015

At a glance

  • Drugs HF 10 (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Takara Bio
  • Most Recent Events

    • 12 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 May 2014 Planned End Date changed from 1 Mar 2014 to 1 Sep 2014 as reported by Clinicalrials.gov.
    • 10 Apr 2014 Status changed from recruiting to active, no longer recruiting, as reported by a Takara Bio media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top